INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 18, 2025, Sarepta issued a press release disclosing the death of "a young man with Duchenne muscular dystrophy . . . following treatment with ELEVIDYS", Sarepta's Duchenne muscular dystrophy drug, "having suffered acute liver failure."

On this news, Sarepta's stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025.

Then, on June 16, 2025, Sarepta issued a press disclosing a second fatality from acute liver failure in a patient treated with Elevidys. As a results, Sarepta halted its ongoing clinical trial and temporarily suspended distribution of Elevidys for patients who are no longer able to walk.

On this news, Sarepta's stock price fell $15.24 per share, or 42.12%, to close at $20.94 per share on June 16, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP

View the original press release on ACCESS Newswire